Making the Most of Your Molecular Biology Platform: Why qPCR and ddPCR Success Starts Before the Assay Runs

As molecular biology plays a larger role in advanced therapeutic development, sponsors are asking more from their qPCR and ddPCR programs than ever before. The growth of cell and gene therapies, biodistribution studies, rare target detection, and complex nucleic acid-based endpoints has created a greater need for sensitive, reliable, and scientifically defensible molecular data.

For many sponsors, the first question is often a technology question: Should we use qPCR or ddPCR?

It is an important question, but it is rarely the only question that matters.

At Smithers Pharmaceutical Development Services, the molecular biology team works with sponsors to look beyond the instrument itself and evaluate the full analytical strategy surrounding each assay. That means considering sample handling, extraction methods, assay optimization, sensitivity requirements, normalization strategy, data interpretation, and regulatory expectations from the beginning.

Because in molecular biology, the quality of the final data is shaped long before the first amplification curve or droplet count is generated.

Demand Is Rising for More Sensitive Molecular Methods

Across the pharmaceutical and biotechnology industry, sponsors are increasingly working with therapies that require detection of very small biological signals. In cell and gene therapy development especially, molecular assays may need to identify rare targets, quantify low-copy genetic material, or evaluate biodistribution across complex biological matrices.

This has naturally increased interest in platforms such as qPCR and ddPCR. Both technologies can be powerful tools, but the demand for greater sensitivity has also revealed a common challenge: sensitivity is not created by the PCR platform alone.

A sponsor may select ddPCR because they have heard it offers stronger sensitivity. Another may select qPCR because they believe it will be more cost-effective. In both cases, the decision can be incomplete if it is made without understanding the full assay workflow.

The best molecular biology programs begin by asking what purpose, decision risk, study phase, and regulatory context are.

Only then can the right platform and the right supporting strategy be selected.

qPCR and ddPCR Are Only Part of the Whole Package

For many sponsors, molecular biology support is still viewed primarily through the lens of qPCR and ddPCR. Those platforms matter, of course, but they are only one part of a much larger scientific process.

Before an assay can produce meaningful data, samples must be collected, handled, and processed in a way that protects the integrity of the target. Extraction methods must be optimized to support recovery, purity, reproducibility, and sensitivity. Assay conditions must be evaluated carefully. Controls, standards, normalization strategies, and acceptance criteria must be designed with the end use of the data in mind.

This is where experienced molecular biology support becomes especially valuable.
At Smithers, the team has spent years refining methodologies and identifying better strategies for complex molecular assays. That experience allows the team to help sponsors think through not only which platform to use, but how to build an assay that is more likely to produce reliable and useful results.

In practical terms, this means sponsors are not simply purchasing a qPCR or ddPCR run. They are gaining access to scientific guidance that can help shape the program from the earliest technical decisions through final data interpretation.

The Cheapest Platform Is Not Always the Most Cost-Effective Strategy

One of the most common misconceptions in molecular biology testing is that qPCR is automatically the less expensive choice and ddPCR is automatically the premium option.
In reality, cost depends on far more than the name of the platform.

If a qPCR assay requires extensive troubleshooting, optimization, repeat testing, or additional work to meet sensitivity expectations, it may not be the most efficient path forward. Conversely, if a ddPCR assay is already well suited to the target, matrix, and sensitivity requirements, it may provide a more direct and effective approach.

This is why Smithers encourages sponsors to evaluate cost in the context of the complete assay development process.

The right question is not simply, “Which platform costs less?” The better question is, “Which strategy gives this program the best chance of generating the right data at the right time?”

That broader view can help sponsors avoid delays, unnecessary rework, and data packages that fall short of their intended purpose.

Sensitivity Often Starts With Extraction

Another frequent misconception is that sensitivity is achieved only by choosing a more sensitive amplification platform.

In many cases, assay sensitivity is heavily influenced by what happens before amplification begins. Extraction efficiency, sample input, matrix effects, target stability, and workflow consistency can all have a meaningful impact on performance.

A strong ddPCR assay cannot compensate for poor extraction. A well-designed qPCR assay can underperform if upstream sample preparation is not optimized. Conversely, thoughtful extraction strategies can help unlock improved sensitivity and reproducibility across molecular platforms.

This is one of the areas where Smithers’ experience is especially important. By evaluating extraction methods and sample preparation strategies as part of the broader assay design, the molecular biology team helps sponsors improve the performance of the entire workflow rather than relying on platform selection alone.

For sponsors working with rare targets or limited sample volumes, that upstream strategy can be critical.

Data Must Be Designed for Interpretation

Generating molecular data is not enough. Sponsors also need data that can be interpreted, defended, and used to support development decisions.

This is especially important when considering normalization strategies. A sponsor may initially believe they only need an assay for a single gene of interest. However, without appropriate normalization and supporting context, the resulting data may not answer the questions regulators, internal decision-makers, or development teams will eventually ask.
This can create significant risk.

A study may produce large amounts of data, only for the sponsor to discover later that essential interpretive elements are missing. That can lead to uncertainty, additional studies, or difficult regulatory discussions.

Smithers works with sponsors to think through these considerations early. By helping define how data will be normalized, analyzed, and positioned within the broader program, the team helps sponsors build molecular biology strategies that are more complete from the start.

Supporting Sponsors at Every Level of Experience

The need for education and strategic guidance is especially clear among emerging biotechnology companies. Many small and mid-sized sponsors are advancing highly innovative therapies, but they may not have dedicated internal bioanalytical leaders with deep molecular biology experience.

For these teams, an experienced partner can provide critical support in shaping the right approach.

At the same time, larger pharmaceutical companies also benefit from external molecular biology expertise. Even when internal teams are highly experienced, complex programs often require additional perspective, specialized methods, or a partner that can help evaluate the best strategy for a specific target, matrix, or application.

Smithers’ role is not only to execute assays, but to collaborate with sponsors, share experience, and help guide decision-making. That consultative approach can be valuable whether a sponsor is building its first molecular biology program or refining an advanced strategy for a late-stage development effort.

A Better Way to Think About Molecular Biology Support

The most successful molecular biology programs do not begin with the assumption that one platform is always better than another. They begin with a careful understanding of the science, the sample, the target, the sensitivity requirement, and the intended use of the data.
qPCR and ddPCR remain essential tools, but they are most powerful when supported by the right strategy.

For sponsors developing complex therapies, the question should not be limited to whether they need qPCR or ddPCR. The more important question is whether their molecular biology program has been designed to generate data that is sensitive, reliable, interpretable, and aligned with the needs of the broader development pathway.

At Smithers Pharmaceutical Development Services, that is where molecular biology support begins